Principal Financial Group Inc. Boosts Stock Position in Krystal Biotech, Inc. $KRYS

Principal Financial Group Inc. raised its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 1.4% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 142,843 shares of the company’s stock after buying an additional 1,960 shares during the quarter. Principal Financial Group Inc. owned about 0.49% of Krystal Biotech worth $25,216,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of KRYS. Atle Fund Management AB lifted its position in Krystal Biotech by 109.3% during the third quarter. Atle Fund Management AB now owns 42,191 shares of the company’s stock valued at $7,448,000 after acquiring an additional 22,033 shares during the last quarter. Transcend Capital Advisors LLC acquired a new position in shares of Krystal Biotech during the third quarter worth $297,000. Privium Fund Management B.V. lifted its holdings in shares of Krystal Biotech by 30.6% during the 3rd quarter. Privium Fund Management B.V. now owns 12,170 shares of the company’s stock valued at $2,148,000 after purchasing an additional 2,850 shares during the last quarter. AlphaQuest LLC boosted its position in shares of Krystal Biotech by 14.7% in the 3rd quarter. AlphaQuest LLC now owns 664 shares of the company’s stock worth $117,000 after purchasing an additional 85 shares in the last quarter. Finally, Arizona State Retirement System grew its stake in Krystal Biotech by 1.3% during the 3rd quarter. Arizona State Retirement System now owns 6,397 shares of the company’s stock worth $1,129,000 after buying an additional 81 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Trading Up 1.9%

Shares of NASDAQ KRYS opened at $272.74 on Friday. Krystal Biotech, Inc. has a 12-month low of $122.80 and a 12-month high of $295.98. The stock has a market cap of $7.91 billion, a PE ratio of 40.89 and a beta of 0.49. The company has a 50-day moving average of $256.88 and a 200 day moving average of $201.48.

Analyst Ratings Changes

KRYS has been the subject of several recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $310.00 price target (up previously from $240.00) on shares of Krystal Biotech in a report on Friday, January 9th. Guggenheim set a $224.00 target price on shares of Krystal Biotech and gave the stock a “buy” rating in a research note on Friday, October 17th. Zacks Research lowered shares of Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research note on Thursday. Citigroup lifted their price objective on shares of Krystal Biotech from $320.00 to $336.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Krystal Biotech in a research note on Monday, December 29th. Nine equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $277.89.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the completion of the sale, the insider owned 1,413,711 shares in the company, valued at $311,242,613.76. This trade represents a 1.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 13.70% of the stock is currently owned by company insiders.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.